# Aculys Pharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/aculys-pharma

- Industry: Pharmaceuticals
- Headquarters: Tokyo, Japan
- Website: www.aculys.com/
- Total disclosed funding: $114M
- Latest round: Series C (Mar 24, 2025)
- Investors on record: 12

## About

Based in Japan, Aculys Pharma, Inc. is focused on advancing therapeutic solutions in neurology and psychiatry, particularly targeting unmet medical needs such as drug-resistant epilepsy and obstructive sleep apnea.Aculys Pharma, Inc. is a pharmaceutical company dedicated to developing innovative treatments for neurological and psychiatric disorders. Founded in 2021 in Tokyo, Japan, by Kazunari Tsunaba, the company has secured a total of JPY 4.4 billion through its Series C funding round on March 24, 2025. This funding was provided by a combination of new investors, including KB Investment and SBI Investment, along with returning investors Catalys Pacific and HBM Partners. Aculys Pharma has completed 3 deals to date.Aculys Pharma, Inc. specializes in developing pharmaceutical products to meet unmet medical needs in neurology and psychiatry. The company is focused on innovative therapies targeting conditions such as drug-resistant epilepsy and obstructive sleep apnea. Currently, they are working on a nasal formulation of diazepam and pitolisant aimed at enhancing the quality of life for patients. Their offerings are primarily directed at the Japanese market, with aspirations to introduce therapies that have gained approvals in European and American markets, addressing drug lag and drug loss issues in Japan.Aculys Pharma generates revenue through the commercialization of its pharmaceutical products, leveraging partnerships with healthcare providers and distributors. Their transaction model includes direct-to-consumer sales and collaborations with hospitals and clinics, focusing on the distribution of flagship products like the nasal diazepam and pitolisant formulations. Revenue strategies are tailored to align with the competitive pharmaceutical landscape, facilitating access to their medical solutions for patients and caregivers facing neurological and psychiatric challenges.Aculys Pharma plans to utilize the JPY 4.4 billion raised in its Series C funding to advance the commercialization of its therapeutic products in Japan. The company is focused on launching new products designed to address specific medical needs, with a strategy to expand its market presence in the Japanese healthcare sector. They aim to increase accessibility to their innovative therapies, which have already gained traction in international markets.

## Funding rounds

- Series C, Mar 24, 2025, $30M — HBM Partners, KB Investment, SBI Investment, Catalys Pacific
- Series B, Feb 22, 2022, $24M — HBM Partners, Sumitomo Mitsui Trust Investment, Mitsubishi UFJ Capital, Global Founders Capital, ANRI, Spiral Capital, JIC Venture Growth Investments, Vision Pacific LifeSciences Capital
- Series A, Oct 27, 2021, $61M — HBM Partners, Sumitomo Mitsui Trust Investment, Global Founders Capital, ANRI, SB Investment Advisers, Catalys Pacific

## Investors

- HBM Partners (https://capitalatlas.ai/funds/hbm-partners) — Series A, Series B, Series C
- Sumitomo Mitsui Trust Investment (https://capitalatlas.ai/funds/sumitomo-mitsui-trust-investment) — Series A, Series B
- Global Founders Capital (https://capitalatlas.ai/funds/global-founders-capital) — Series A, Series B
- ANRI (https://capitalatlas.ai/funds/anri) — Series A, Series B
- SB Investment Advisers (https://capitalatlas.ai/funds/sb-investment-advisers) — Series A
- Catalys Pacific (https://capitalatlas.ai/funds/catalys-pacific) — Series A, Series C
- Mitsubishi UFJ Capital (https://capitalatlas.ai/funds/mitsubishi-ufj-capital) — Series B
- Spiral Capital (https://capitalatlas.ai/funds/spiral-capital) — Series B
- JIC Venture Growth Investments (https://capitalatlas.ai/funds/jic-venture-growth-investments) — Series B
- Vision Pacific LifeSciences Capital — Series B
- KB Investment (https://capitalatlas.ai/funds/kb-investment) — Series C
- SBI Investment (https://capitalatlas.ai/funds/sbi-investment) — Series C